Protein kinase Ci (PKCi) promotes non-small cell lung cancer (NSCLC) by binding to Par6a and activating a Rac1-Pak-Mek1,2-Erk1,2 signaling cascade. The mechanism by which the PKCi-Par6a complex regulates Rac1 is unknown. Here we show that epithelial cell transforming sequence 2 (Ect2), a guanine nucleotide exchange factor for Rho family GTPases, is coordinately amplified and overexpressed with PKCi in NSCLC tumors. RNA interference-mediated knockdown of Ect2 inhibits Rac1 activity and blocks transformed growth, invasion and tumorigenicity of NSCLC cells. Expression of constitutively active Rac1 (RacV12) restores transformation to Ect2-deficient cells. Interestingly, the role of Ect2 in transformation is distinct from its well-established role in cytokinesis. In NSCLC cells, Ect2 is mislocalized to the cytoplasm where it binds the PKCi-Par6a complex. RNA interference-mediated knockdown of either PKCi or Par6a causes Ect2 to redistribute to the nucleus, indicating that the PKCi-Par6a complex regulates the cytoplasmic localization of Ect2. Our data indicate that Ect2 and PKCi are genetically and functionally linked in NSCLC, acting to coordinately drive tumor cell proliferation and invasion through formation of an oncogenic PKCi-Par6a-Ect2 complex.
Introduction
Epithelial cell transforming sequence 2 (Ect2) is a guanine nucleotide exchange factor (GEF) for Rho family GTPases that functions in cytokinesis (Tatsumoto et al., 1999; Kim et al., 2005; Niiya et al., 2005 Niiya et al., , 2006 Hara et al., 2006) . Ect2 is comprised of a C-terminal GEF domain, and an N-terminal regulatory domain that modulates Ect2 activity and localization (Kim et al., 2005) . Ectopic expression of the Ect2 GEF domain causes transformation in mouse fibroblasts, whereas full-length Ect2 does not (Miki et al., 1993; Saito et al., 2004) . The relevance of this observation to human cancer is unclear. Human cancers express only full-length Ect2, indicating that the transforming C-terminal Ect2 fragment is not relevant to human cancer (Saito et al., 2003) . Paradoxically, Ect2 is overexpressed in some human tumors (Sano et al., 2006; Salhia et al., 2008; Zhang et al., 2008; Hirata et al., 2009 ) and transient Ect2 knockdown (KD) induces transitory cell cycle arrest in vitro, indicating a possible role for Ect2 in tumor cell growth (Hirata et al., 2009 ). However, the mechanism of Ect2 involvement in human tumorigenesis remains unresolved.
Here we report a novel genetic, biochemical and functional link between Ect2 and the protein kinase Ci (PKCi) oncogene. Ect2 and PKCi are coordinately overexpressed in primary non-small cell lung cancer (NSCLC) tumors as a consequence of tumor-specific coamplification of the ECT2 and PRKCI genes. Furthermore, Ect2 is required for transformed growth and invasion of NSCLC cells in vitro and tumorigenicity in vivo. The role of Ect2 in transformation is distinct from its well-characterized function in cytokinesis. Ect2 mislocalizes to the cytoplasm of NSCLC cells where it binds the oncogenic PKCi-Par6a complex and activates Rac1. Furthermore, the PKCi-Par6a complex regulates the cytoplasmic mislocalization and oncogenic function of Ect2. Thus, Ect2 and PKCi are genetically linked by co-amplification, and functionally linked through their physical association in an oncogenic PKCi-Par6a-Ect2 complex that drives transformation through Rac1.
Results
Ect2 and PKCi are coordinately amplified and overexpressed in primary NSCLC tumors The gene encoding Ect2 resides on chromosome 3q26, a region frequently amplified in lung squamous cell carcinoma (LSCC) (Brass et al., 1996; Balsara et al., 1997; Sugita et al., 2000) . To assess Ect2 expression, we analysed 137 primary lung tumors (68 lung adenocarcinoma (LAC) and 69 LSCC) and matched normal lung by quantitative real-time PCR (qPCR). Ect2 mRNA was significantly higher in LAC (mean 4.6-fold increase; Po0.0001) and LSCC (mean 6.8-fold increase; Po0.0001) tumors than matched normal lung ( Figure 1a ). Elevated Ect2 mRNA (defined as >2 s.d. above the mean Ect2 mRNA value of matched normal lung) was observed in 113/137 (82%) of NSCLC tumors and was equally prevalent in LAC and LSCC.
We next assessed ECT2 copy number. In all, 67 of 94 (71%) LSCC tumors exhibited ECT2 amplification (defined as a gain of one or more ECT2 alleles). Analysis of 40 LAC tumors revealed no increase in ECT2 copy number (data not shown), consistent with the restricted distribution of 3q26 amplification to LSCC tumors (Brass et al., 1996; Balsara et al., 1997; Sugita et al., 2000) . LSCC tumors harboring ECT2 amplification showed significantly higher Ect2 mRNA than tumors lacking amplification (Po0.001) ( Figure 1b ). PRKCI is adjacent to ECT2 on chromosome 3q26 and is a target of frequent tumor-specific gene amplification in LSCC tumors (Regala et al., 2005b) . ECT2 copy number showed a statistically significant, positive correlation with PRKCI copy number (Figure 1c , R 2 of 0.76, Po0.00001). In addition, PKCi and Ect2 mRNA expression correlate in LSCC harboring 3q26 gene amplification ( Figure 1d ; R 2 of 0.58, Po0.00001). Thus, ECT2 and PRKCI are co-amplified and coordinately overexpressed in LSCC tumors.
Immunohistochemical analysis reveals that Ect2 is restricted to the nucleus of normal lung epithelial cells (Figure 2a , left panel). In contrast, LAC and LSCC tumors display increased Ect2 staining in the cytoplasm (Figures 2b and c, left panels). Staining specificity was confirmed using a 10-fold excess of recombinant Ect2 peptide in the antibody solution, which significantly inhibited Ect2 staining (Figure 2a -c, right panels). Analysis of 68 primary NSCLC tumors (36 LSCC and 32 LAC) revealed elevated cytoplasmic Ect2 staining in 57/68 or B84% of tumors, showing that Ect2 protein is frequently overexpressed in NSCLC tumors.
Ect2 is required for anchorage-independent growth and invasion of NSCLC cells We next assessed whether Ect2 has a role in the transformed phenotype of NSCLC cells. H1703 LSCC cells were analysed because they harbor B4-fold increase in ECT2 copy number and express abundant Ect2 protein. Cells were stably transduced with one of three lentiviral Ect2 RNA interference (RNAi) con- Figure 1 Epithelial cell transforming sequence 2 (Ect2) and protein kinase Ci (PKCi) are coordinately amplified and overexpressed in primary non-small cell lung cancer (NSCLC) tumors. Ect2 is overexpressed in primary lung adenocarcinoma (LAC) and squamous cell carcinoma (LSCC) (a). Sixty-eight LAC cases, 69 LSCC cases and matched normal control lung tissues were analysed by quantitative real-time PCR for Ect2 mRNA abundance. Ect2 mRNA is significantly higher in LAC and LSCC tumor samples than in matched normal lung (*Po0.0001 and Po0.0001, respectively). (b) ECT2 gene amplification drives Ect2 expression in LSCC. LSCC tumors were analysed for ECT2 gene copy number as described in Materials and methods. Tumors harboring ECT2 gene amplification express higher Ect2 mRNA than tumors without ECT2 amplification (*Po 0.001). (c) ECT2 and PRKCI are co-amplified in LSCC. ECT2 and PRKCI gene copy number exhibit a significant correlation in NSCLC tumors (n ¼ 94; R 2 ¼ 0.76; *Po0.00001). (d) Ect2 and PKCi mRNA are coordinately overexpressed in LSCC tumors harboring gene amplification (n ¼ 67; R 2 ¼ 0.52; *Po0.00001).
Figure 2
Epithelial cell transforming sequence 2 (Ect2) is overexpressed and mislocalized to the cytoplasm in primary non-small cell lung cancer tumors. Immunohistochemical localization of Ect2 in normal lung epithelium (a), lung adenocarcinoma (LAC) (b) and lung squamous cell carcinoma (LSCC) (c) was carried out as described in Materials and methods. Ect2 localizes predominantly to the nucleus of normal lung epithelial cells (a). Ect2 is overexpressed in both LAC (b) and LSCC (c) tumors, and is mislocalized to the cytoplasm of tumor cells. Ect2 staining specificity was confirmed using an excess of Ect2 peptide in the antibody solution (a-c, Ect2 þ peptide). structs or a non-target (NT) RNAi control lentivirus, and cell populations were assessed for Ect2 mRNA abundance and protein expression ( Figure 3a ). Each of the three Ect2 RNAi constructs induced a reduction in Ect2 mRNA and protein when compared with NT cells (Figure 3a ). Functionally, Ect2 KD cells exhibited impaired anchorage-independent growth ( Figure 3b ) and invasion ( Figure 3c ) commensurate with the level of Ect2 KD. To confirm that this cellular phenotype is due to Ect2 KD, we expressed RNAi-resistant, GFP-tagged Ect2 in NT and Ect2 KD cells ( Figure 3d ). Exogenous Ect2 significantly restored anchorage-independent growth ( Figure 3e ) and invasion ( Figure 3f ) in Ect2 KD cells but had no effect on NT cells. We also analysed a panel of four cell lines representing major subtypes of NSCLC, LAC (A549 and H358), large-cell lung carcinoma (H460) and LSCC (A427) ( Supplementary Figure 2) . Each cell line exhibited a significant inhibition of anchorage-independent growth and invasion after Ect2 KD indicating that Ect2 is important for transformation in many NSCLC cell lines.
Ect2 is important for NSCLC tumorigenicity in vivo We next assessed the role of Ect2 in NSCLC tumorigenicity in vivo. A549 cells were chosen because they grow as subcutaneous tumors with well-established growth kinetics. A549/Ect2 KD and A549/NT cells were injected subcutaneously into the flanks of athymic nude mice and tumor growth was monitored over 4 weeks. A549/Ect2 KD cells exhibited impaired tumor growth when compared with A549/NT cells ( Figure 4a ). Immunohistochemical analysis confirmed reduced Ect2 expression in A549/Ect2 KD tumors ( Figure 4b ). A549/Ect2 KD tumors exhibited a significant 2.3-fold reduction in labeling index (defined as BrdU-labeled nuclei/total nuclei) compared with A549/NT tumors ( Figure 4c ). In contrast, A549/NT and A549/Ect2 KD tumors exhibited no significant difference in TUNELpositive nuclei (0.19 ± 0.05% in A549/NT tumors versus 0.19 ± 0.09% in A549/Ect2 KD tumors; P>0.97) or CD31 staining (Figure 4d ), indicating that Ect2 KD primarily affects tumor cell proliferation.
Ect2 KD does not induce cytokinesis defects in NSCLC cells
A major physiologic function of Ect2 is the regulation of cytokinesis (Tatsumoto et al., 1999; Niiya et al., 2005; Hara et al., 2006) . Ect2 KD in non-transformed cells leads to a cytokinesis defect characterized by decreased cell growth and accumulation of multinucleated cells (Tatsumoto et al., 1999) . To determine whether Ect2 KD in NSCLC cells affects cytokinesis, A549, H1703 and Madin-Darby canine kidney (MDCK) cells were stably transduced with either Ect2 or NT RNAi. The target sequence of Ect2 RNAi construct #3 is conserved Figure 3 Epithelial cell transforming sequence 2 (Ect2) is important for anchorage-independent growth and invasion of non-small cell lung cancer cells. H1703 cells were infected with one of three recombinant lentiviruses containing RNA interference (RNAi)-targeting Ect2 (Ect2-RNAi #1-3) or a non-target (NT) sequence. Cell populations stably transduced with each RNAi were isolated and analysed as described in Materials and methods. (a) Cells expressing Ect2-RNAi or NT-RNAi constructs were assessed for Ect2 mRNA abundance by quantitative real-time PCR and Ect2 protein by immunoblot analysis. Cells expressing Ect2-RNAi or NT-RNAi were analysed for anchorage-independent growth in soft agar (b) and cellular invasion through Matrigel-coated chambers (c). Ect2-RNAi (construct #3) and NT-RNAi cells were transfected with a plasmid expressing GFP-Ect2 ( þ Ect2) or a control empty plasmid, and assessed for GFP-Ect2 and endogenous Ect2 expression by immunoblot analysis (d). Cells from d were assessed for anchorageindependent growth in soft agar (e) and invasion (f). Data in panels a-c, e and f are expressed as % NT control and represent the mean±s.e.m.; n ¼ 3. *denotes a statistically significant difference from NT; **denotes a statistically significant difference from Ect2 knockdown cells in the absence of GFP-Ect2, Po0.05).
Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields between human and canine Ect2 resulting in efficient Ect2 KD in all three cell lines ( Figure 5a ). As expected, MDCK/Ect2 KD cells exhibited an increased population-doubling time (PDT) compared with MDCK/NT cells ( Figure 5b ). In contrast, neither A549/Ect2 KD nor H1703/Ect2 KD cells showed a significant change in PDT compared with their NT cells ( Figure 5b ). Furthermore, MDCK/Ect2 KD cell cultures exhibited an accumulation of large, multinucleated cells, which was not observed in A549/Ect2 KD or H1703/Ect2 KD cell cultures (Figure 5c ). Quantitative analysis revealed a 12-fold increase in multinucleated cells in MDCK/Ect2 KD cultures but no significant change in A549/Ect2 KD or H1703/Ect2 KD cultures when compared with their respective NT cell cultures ( Figure 5d ). We also observed no accumulation of multinucleated cells in A549/Ect2 KD tumors in vivo (1.3±0.10% in A549/NT cells versus 1.3 ± 0.15% in A549/Ect2 KD cells; P ¼ 0.98, n ¼ >500 cells counted per tumor). These data indicate that the role of Ect2 in transformation is distinct from its role in cytokinesis.
Ect2 regulates Rac1 activity in NSCLC cells
As Ect2 can regulate the activity of the Rho GTPases Rac1, Cdc42 and RhoA in vitro (Miki et al., 1993) , we assessed Rho GTPase activity in H1703/Ect2 KD and H1703/NT cells. Ect2 KD cells exhibited decreased Rac1 activity, but no change in Cdc42 or RhoA activity compared with NT cells (Figure 6a ). Quantitative analysis revealed a significant B50% inhibition in Rac1 activity in Ect2 KD cells (Figure 6b ). Furthermore, expression of a constitutively active Rac1 allele (RacV12) in H1703/Ect2 KD and H1703/NT cells ( Figure 6c ) restored anchorage-independent growth and invasion in Ect2 KD cells, although having no effect in NT cells (Figures 6d and e ). Similar results were observed in A549 cells (data not shown).
Figure 4
Epithelial cell transforming sequence 2 (Ect2) is required for non-small cell lung cancer tumorigenicity in vivo. A549/nontarget (NT) and A549/Ect2 knockdown (KD) cells were injected subcutaneously into the flanks of nude mice and tumor volumes were determined over a 4-week period as described in Materials and methods. (a) A549/Ect2 KD tumors grow significantly slower than A549/NT cell tumors. *indicates a statistically significant difference between A549/NT and A549/Ect2 KD tumor volumes at the indicated time points (Po0.05). (b) A549/NT and A549/Ect2 KD tumors stained with hematoxylin and eosin or Ect2 by immunohistochemistry. Ect2 expression is diminished in A549/Ect2 KD tumors. (c) BrdU staining of A549/NT and A549/Ect2 KD tumors (inset). BrdU-positive nuclei were counted as described in Materials and methods. A549/Ect2 KD tumors exhibit a statistically significant decreased in BrdU labeling index when compared with A549/NT tumors (*Po0.05). (d) A549/NT and A549/Ect2 KD tumors exhibited no differences in TUNEL or CD31 staining.
Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields Rac1 drives tumor cell proliferation by activating a Pak-Mek1,2-Erk1,2 proliferative signaling pathway . Therefore, we assessed the status of this pathway in A549/NT and A549/Ect2 KD tumors in vivo. Immunoblot analysis confirmed that A549/Ect2 KD tumors express less Ect2 than A549/NT tumors (Figure 7a ). Quantitative analysis reveals a significant B5-fold decrease in Ect2 protein in A549/Ect2 KD tumors (Figure 7b ). A549/Ect2 KD tumors exhibit lower phospho-298 Mek1,2 than A549/NT tumors with no change in total Mek1,2 ( Figure 7a ) resulting in a decreased ratio of phospho-298-Mek1,2 to total Mek1,2 ( Figure 7c ). A similar decrease in phospho-Erk1,2 (without a change in total Erk1,2) is observed in A549/Ect2 KD tumors (Figure 7a ), resulting in a decreased ratio of phospho-Erk1,2 to total Erk1,2 ( Figure 7d ). No evidence for PARP cleavage, a biochemical marker of apoptosis, was observed in either A549 Ect2 KD or NT tumors (Figure 7a ), consistent with our tumor terminal deoxynucleotidyltransferasemediated dUTP nick-end labeling (TUNEL) staining.
Thus, Ect2 KD inhibits the Rac1-Pak-Mek1,2-Erk1,2 proliferative signaling pathway in vivo.
Ect2 associates with the PKCi-Par6a complex in NSCLC cells Both Ect2 and the PKCi-Par6a complex regulate Rac1 signaling in NSCLC cells. Therefore, we assessed whether Ect2 binds the PKCi-Par6a complex (Figure 8 ). As commercially available Par6 antibodies do not efficiently detect Par6a, we generated MDCK and H1703 cells expressing Flag-tagged wild-type human Par6a (wtPar6) or empty plasmid (Vector). Immunoblot analysis confirmed expression of endogenous Ect2, PKCi and Flag-Par6a in MDCK/wtPar6 cells (Figure 8a, lysate) . When PKCi was immunoprecipitated from MDCK/Vector and MDCK/wtPar6 cells, Ect2 was detected as a faint band after a long exposure; however, Flag-Par6a efficiently co-precipitated with PKCi in MDCK/wtPar6 cells as expected (Figure 8a , PKCi IP). Similarly, when Flag-Par6a was immuno- Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields precipitated from MDCK/wtPar6 cells, abundant PKCi, but very little Ect2, was detected in the resultant precipitates (Figure 8a, Flag IP) . In contrast, when PKCi was immunoprecipitated from H1703/wtPar6 cells, both endogenous Ect2 and Flag-Par6a were easily detected in the resultant precipitates (Figure 8b , PKCi IP). Likewise, both Ect2 and PKCi efficiently coprecipitated with Flag-Par6a in H1703/wtPar6 cells (Figure 8b , Flag IP). Thus, a significant amount of Ect2 associates with PKCi-Par6a in NSCLC cells, whereas only a small amount of Ect2 is found in association with PKCi-Par6a in MDCK cells.
To further determine whether Ect2 binds the PKCi-Par6a complex, H1703/PKCi KD cells were transfected with either Flag-tagged wild-type PKCi, a PKCi-D63A mutant, which does not bind Par6a , or control plasmid (Vector) (Figure 8c ). Immunoblot analysis confirmed expression of Ect2, Flag-wildtype PKCi and Flag-PKCi-D63A in these cells (Figure 8c, lysate) . Immunoprecipitation of Flag-PKCi revealed that Ect2 associates with wtPKCi, but not PKCi-D63A (Figure 8c , Flag IP). A complementary experiment was conducted in which H1703/Par6a KD cells were transfected with either wild-type Par6a or a Par6a-K19A mutant, which does not bind PKCi (Figure 8d ). Immunoblot analysis confirmed the expression of Ect2, PKCi and the appropriate Flag-Par6a alleles in these cells (Figure 8d, Lysate) . Both PKCi and Ect2 co-immunoprecipitated with wild-type Par6a, but neither PKCi nor Ect2 immunoprecipitated with Flag-Par6a-K19A (Figure 8d, Flag IP) . These results indicate that Ect2 preferentially binds to the PKCi-Par6a complex when compared with PKCi or Par6a alone. Similar results were obtained in A549 cells (data not shown).
Cytoplasmic localization of Ect2 in NSCLC cells is regulated by PKCi and Par6a
As Ect2 is mislocalized to the cytoplasm of NSCLC tumors (Figure 2) , we examined Ect2 localization by confocal immunofluorescence microscopy (Figure 9 ). Ect2 is almost exclusively nuclear in MDCK cells (Figure 9a ). In contrast, Ect2 localizes to both the nucleus and cytoplasm of H1703/NT cells (Figure 9b ). Interestingly, both H1703/PKCi KD and H1703/Par6a KD cells showed significantly less cytoplasmic Ect2 staining than H1703/NT cells (Figures 9c and d) , indicating that PKCi and Par6a regulate cytoplasmic Ect2 localization. QPCR confirmed efficient PKCi and Par6a KD respectively in these cells ( Supplementary  Figure 3) . A similar change in Ect2 localization from cytoplasm to nucleus was observed in A549/PKCi KD cells (Supplementary Figure 4) .
The effects of PKCi KD and Par6a KD on Ect2 localization were confirmed by cellular fractionation (Figure 10 ). Ect2 is predominantly nuclear in MDCK cells (Figure 10a ). In contrast, H1703/NT cells express equal amounts of Ect2 in nuclear and cytoplasmic fractions, consistent with our immunofluorescence results (Figure 10b ). H1703/PKCi KD and H1703/ Par6a KD cells exhibit an increase in nuclear Ect2 and a concomitant decrease in the cytoplasmic Ect2 (Figure 10b ). Total Ect2 in H1703/PKCi KD and Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields H1703/Par6a KD cells was comparable with H1703/NT cells, indicating that PKCi KD and Par6a KD primarily affect Ect2 localization, and not expression. The purity of cellular fractions was confirmed using nuclear (lamins A/C) and cytoplasmic (Mek1,2) markers (Figure 10a and b). As expected, PKCi is predominantly cytoplasmic in MDCK and H1703 cells and was efficiently knocked down in H1703/PKCi KD cells (Figures 10a  and b ). Quantitative analysis of three independent experiments confirmed that Ect2 is largely nuclear in MDCK cells but is distributed equally between the nucleus and cytoplasm of H1703/NT cells, and that H1703/PKCi KD and H1703/Par6a KD cells exhibit a significant redistribution of Ect2 from the cytoplasm to the nucleus (Figure 10c ).
Discussion
Rho family GTPases are regulated by GEFs. As Rac1 activity is high in NSCLC cells as a result of the PKCi-Par6a complex Frederick et al., 2008) , we hypothesized that a Rac1-GEF may bind the PKCi-Par6a complex to regulate Rac1 activity in NSCLC tumors. The Ect2 GEF is an attractive candidate for such a role as the Ect2 gene, ECT2, is located at chromosome 3q26, and elevated Ect2 mRNA and protein has been reported in human gliomas, lung, esophageal and pancreatic cancers (Takai et al., 1995; Sano et al., 2006; Zhang et al., 2008; Hirata et al., 2009) . Here, we show that ECT2 and PRKCI are co-amplified as part of the 3q26 amplicon, leading to coordinate overexpression of Ect2 and PKCi in LSCC tumors. Our data provide the first evidence that Ect2 and PKCi are genetically linked in human cancer, and reveal that Ect2 is a relevant target of the 3q26 amplicon. We also show that Ect2 is functionally important in anchorage-independent growth and invasion of NSCLC cells in vitro and tumorigenicity in vivo. Our data are consistent with several recent reports implicating Ect2 in the growth and invasion of cancer cells in vitro (Salhia et al., 2008; Hirata et al., 2009) . Our results provide important new mechanistic insight into how Ect2 participates in transformation and extend previous findings to the in vivo setting. Ect2 KD blocks tumorigenicity by inhibiting tumor cell proliferation, without affecting tumor apoptosis or vascularization. Furthermore, we show that Ect2 selectively regulates Rac1 activity in NSCLC cells, and Rac1 is a critical downstream effector of Ect2-dependent transformation in vitro. Finally, Ect2 drives tumor cell proliferation by activating a Rac1-Pak-Mek1,2-Erk1,2 signaling axis in vivo. Further studies will be required to dissect the signaling pathway(s) involved in Ect2-, Rac1-dependent invasion. Figure 7 Epithelial cell transforming sequence 2 (Ect2) activates the Pak-Mek1,2-Erk1,2 signaling pathway in vivo. (a) Immunoblot analysis of A549/non-target (NT) and A549/Ect2 knockdown (KD) tumors for Ect2, phospho-298-Mek1,2, total Mek1,2, phospho-Erk1,2, total Erk1,2, actin, and intact and cleaved PARP. Lysates from Hela cells treated with taxol for 48 h were used as positive control for PARP cleavage. (b-d) Quantitative analysis demonstrates a statistically significant decrease in: (b) Ect2 protein expression (n ¼ 4/group; *Po0.0001), (c) phospho-298-Mek1,2/total Mek1,2 ratio (n ¼ 4/group; *Po0.004), and (d) phospho-Erk1,2/total Erk1,2 ratio (n ¼ 4/group; *Po0.03) (d) in A549/Ect2 KD tumors when compared with A549/NT tumors.
Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields Ect2 plays a physiologic role in cytokinesis, suggesting a possible mechanism by which Ect2 KD could block NSCLC cell proliferation. Surprisingly however, although Ect2 KD leads to a severe cytokinesis defect in MDCK cells, no such defect occurs in NSCLC cells in vitro, or A549 tumors in vivo. Our data differ from a recent report that transient Ect2 KD in A549 cells leads to a transitory inhibition of cell cycle (Hirata et al., 2009) . This discrepancy may result from the use of transient Ect2 KD by short interfering RNA as opposed to stable Ect2 KD by lentiviral short hairpin RNA. Our stably transduced Ect2 KD cells may express sufficient Ect2 to remain above a critical threshold required for cytokinesis. Alternatively, NSCLC cells may use a recently described alternative cytokinesis mechanism that makes fibrosarcoma cells resistant to Ect2 KDinduced cytokinesis defects (Kanada et al., 2008) . Our finding that Ect2 KD does not induce a cytokinesis defect (or change in PDT) in any of the five NSCLC cell lines tested argues for the existence of an Ect2independent cytokinesis mechanism in NSCLC cells. Our finding that Ect2 KD in NSCLC cells does not inhibit RhoA, the well-characterized target of Ect2 in cytokinesis (Tatsumoto et al., 1999) , further suggests the existence of such an alternative cytokinesis mechanism. In either case, our analysis reveals a novel Ect2 function in transformation that is distinct from cytokinesis.
Ect2 localizes to the nucleus of MDCK and normal lung epithelial cells. In contrast, Ect2 is overexpressed and mislocalized to the cytoplasm of primary NSCLC tumor cells and NSCLC cell lines. The cytoplasmic mislocalization of Ect2 is reminiscent of the previous observations correlating cytoplasmic mislocalization of Ect2 fragments with transformation. When expressed in mouse fibroblasts, the C-terminal Ect2 GEF domain localized to the cytoplasm, exhibited constitutive GEF activity and caused cellular transformation (Miki et al., 1993; Saito et al., 2004; Solski et al., 2004) . In contrast, full-length Ect2 localized to the nucleus and exhibited no transforming activity (Saito et al., 2004; Solski et al., 2004) .
Our data show that full-length, cytoplasmic Ect2 binds the oncogenic PKCi-Par6a complex in NSCLC cells. Ect2 binds more efficiently to the PKCi-Par6a complex than PKCi or Par6a alone, indicating that both and H1703/wtPar6 (wtPar6) cells were subjected to immunoprecipitation analysis as described in (a). Endogenous Ect2 co-precipitates with both PKCi and Par6a in these cells. (c) H1703/PKCi knockdown (KD) cells were transfected with wtPKCi, a PKCi-D69A mutant or empty plasmid as described in Materials and methods. Total cell lysates confirm expression of Ect2 and Flag-PKCi alleles (Lysates). Immunoprecipitation using Flag antibody co-precipitates Ect2 with wtPKCi but not PKCi-D63A (Flag IP). (d) H1703/Par6a KD cells were transfected with Flag-tagged wtPar6a, Par6a-K19A or empty control plasmid (Vector). Cell lysates confirm expression of Ect2, PKCi and Flag-Par6a alleles (Lysates). Immunoprecipitation using Flag antibody co-precipitates Ect2 and PKCi with wtPar6a but not Par6a-K19A. PKCi and Par6a contribute to Ect2 binding. PKCi or Par6a KD blocks NSCLC cell transformation and leads to redistribution of Ect2 to the nucleus. These data argue that the PKCi-Par6a complex regulates the cytoplasmic localization and oncogenic potential of Ect2. Our data are interesting in light of previous reports that Ect2 can bind the atypical PKC-Par6-Par3 polarity complex at cell-cell junctions in MDCK cells (Liu et al., , 2006 . Our data confirm that a very small amount of Ect2 can be found in association with PKCi and Par6a in MDCK cells; furthermore, we detect very faint Ect2 staining at cellcell junctions in MDCK cells (data not shown). In NSCLC cells, which have lost cellular polarity, Ect2 exhibits punctate staining throughout the cytoplasm, and efficiently binds to the oncogenic PKCi-Par6a complex to activate Rac1 and drive transformation. Further studies will be required to determine the basis for the punctate Ect2 staining pattern, and the molecular mechanisms that regulate the formation, dynamics and activity of the oncogenic PKCi-Par6a-Ect2 complex in NSCLC cells.
In conclusion, our data reveal a novel genetic, biochemical and functional link between PKCi and Ect2 in NSCLC. PKCi and Ect2 are coordinately amplified and overexpressed in NSCLC as part of the 3q26 amplicon. Ect2 has a requisite role in the anchorage-independent growth and invasion of NSCLC cells in vitro and tumorigenicity in vivo. Ect2 is mislocalized to the cytoplasm of NSCLC cells as a consequence of its interaction with the oncogenic PKCi-Par6a complex, and the PKCi-Par6a-Ect2 complex drives transformed growth through activation of a Rac1-Pak-Mek1,2-Erk1,2 signaling axis. Our data are the first to identify Ect2 as a relevant target of tumorspecific 3q26 amplification and to elucidate a molecular mechanism by which Ect2 participates in the transformed phenotype of human tumor cells. Furthermore, our data provide new mechanistic insight into previous observations regarding the cytoplasmic localization of Ect2 fragments and transforming potential. Finally, our data reveal a novel paradigm in which two oncogenes within a single amplicon are genetically, biochemically and functionally linked to cellular transformation. Ect2 and PKCi may be similarly linked in other tumors that harbor 3q26 amplification, such as SCC of the head and neck (Snaddon et al., 2001) , esophagus (Imoto et al., 2001) , cervix (Sugita et al., 2000) and ovary Sugita et al., 2000) .
Materials and methods
Antibody reagents and cell lines Antibodies used are: Ect2, RhoA and CD31/Pecam-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); PKCi, Rac1 and Cdc42 (BD Transduction Labs, San Jose, CA, USA); b-actin, PARP/cleaved PARP, MEK1/2, p298-MEK1/2, ERK, pThr202/Tyr204ERK and Lamin A/C (Cell Signaling, Danvers, MA, USA); FLAG epitope (Sigma-Aldrich, St Louis, MO, USA); BrdU (DAKO, Carpenteria, CA, USA). Phalloidin-Alexa Fluor 594 and anti-Rabbit Alexa Fluor 594 were from Invitrogen (Carlsbad, CA, USA), and TUNEL staining kit from Promega BioSciences (San Luis Obispo, CA, USA). A427, A549, H358, H460, H1703 and MDCK cells were from the American Type Culture Collection (Manassas, VA, USA).
Human primary NSCLC sample analysis
Total RNA was isolated from primary NSCLC tumors and matched normal lung using RNAqueous 4PCR (Ambion, Austin, TX, USA). Ect2 and PKCi mRNA abundance was determined by Taqman qPCR on an Applied Biosystems 7900HT sequence analyzer (Applied Biosystems, Foster City, CA, USA) using 18S for normalization. Primer/probe sets are listed in Supplementary Figure 1a . Genomic DNA was isolated from primary NSCLC tumors and matched normal lung by phenol/chloroform extraction and ECT2 and PRKCI gene copy number was determined by qPCR using the RNASEP1 gene for normalization. Primer/probe sets are listed in Supplementary Figure 1a . Statistical analyses were carried out using the two-tailed Student's t-test and R 2 using Pearson correlation analysis. Results are plotted as % total Ect2 in the nucleus (N) and cytoplasm (C). * , ** , # and ## indicate a statistically significant difference in the amount of nuclear (*and #) and cytoplasmic (**and ##) Ect2 in the indicated cell line when compared with H1703/NT cells (*Po0.02), (**Po0.03), (#Po0.0005) and ( ## Po0.01); n ¼ 3.
Ect2 and PKCi are genetically and functionally linked in NSCLC V Justilien and AP Fields Tissue microarrays of primary NSCLC and matched normal lung were analysed for Ect2 protein by immunohistochemistry using the Envision Plus Dual Labeled Polymer Kit (DAKO). Specificity was determined by incubating primary Ect2 antibody with a 10-fold excess of Ect2 peptide. Images were captured and analysed using an Aperio ScanScope scanner and ImageScope software (Aperio Technologies, Vista, CA, USA).
Lentiviral RNAi constructs, cell transduction and immunoblot analysis Lentiviral RNAi against human Ect2, PKCi and Par6a were obtained from Sigma-Aldrich Mission short hairpin RNA library and packaged into recombinant lentiviruses as previously described . A non-target lentiviral RNAi (NT-RNAi) that does not recognize any human or canine genes was used as a negative control. RNAi target sequences are listed in Supplementary Figure 1b . Stably transduced cell populations were generated as previously described .
Epithelial cell transforming sequence 2, PKCi and Par6a RNAi constructs were analysed for efficiency of target gene KD by qPCR ( Supplementary Figure 1a) . NT, Ect2 and PKCi KD cells were subjected to immunoblot analysis as previously described .
